An interventional study of AP203 mixture (RESCOVIN®) and AP203 mixture (RESCOVIN®) in Upper Respiratory Tract Infection Bacterial, sponsored by AronPharma Sp. z o. o.. Completed at 1 site in Poland. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-11.
Sponsored by AronPharma Sp. z o. o. · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Respiratory Tract Infections with a site in Poland — 2 open to participants now, 3 under way, 1 of them phase 3. Respiratory Tract Infections · Poland.
Among the 20 studies in Respiratory Tract Infections with a site in Poland, this one is the 15th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2022, is one of 5 with no phase, and was the 16th registered.
753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.
Browse Respiratory Tract Infections studies →2 of the 20 studies in Respiratory Tract Infections with a site in Poland are open now. Recruiting first, the newest first:
Lallemand Pharma AG · Sites in Poland
Ages 3–12 · Healthy volunteers
AstraZeneca · Sites in Poland, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 6 · Phase 4 3
First in 2005; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.
Median enrollment 154 across the 18 interventional studies, 3,112 across the 2 observational. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 20 have an industry lead sponsor. The 10 most frequent:
AronPharma Sp. z o. o. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.
AronPharma Sp. z o. o. has 1 study filed under Respiratory Tract Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in Respiratory Tract Infections with a site in Poland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07578012Lallemand Pharma AGPrevention With Ismigen of RTIs in Kids | 2027-03 |
| NCT04769037Helmholtz Zentrum MünchenSupplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Respiratory Tract Infections with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the study was to assess the efficacy and safety of AP203 preparation (RESCOVIN®) in a group of patients with increased incidence to viral and/or bacterial upper respiratory tract infections.
Randomized, double-blind, cross over study conducted under medical supervision on 1) group of 30 patients receiving AP203 mixture in capsule form and 2) group of 30 receiving placebo. After a washout period a group receiving placebo receiver AP203 mixture in syrup form.
The study group was adult patients with an increased incidence of upper respiratory tract infection. During the study, the effect of a mixture of AP203 extracts (RESCOVIN®) on markers of inflammation and oxidative stress and the effect on the incidence of upper respiratory tract infections was assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with an increased incidence of upper respiratory tract infection
Dietary Supplement: AP203 mixture (RESCOVIN®)
Patients with an increased incidence of upper respiratory tract infection
Dietary Supplement: AP203 mixture (RESCOVIN®)
Patients with an increased incidence of upper respiratory tract infection
Other: Placebo
Polyphenol-rich plant extracts Twice a day
Polyphenol-rich plant extracts Twice a day
Twice a day
Efficacy and safety of AP203
Clinical evaluation of the efficacy and safety of AP203, in a group of patients with an increased incidence of viral and/or bacterial upper respiratory tract infections.
Time frame: Baseline, 2 months, 4 months, 6 months
hsCRP level
Comparison of hsCRP level
Time frame: Baseline, 2 months, 4 months, 6 months
8-iso-PGF2IsoP level
Comparison of 8-iso-PGF2IsoP level
Time frame: Baseline, 2 months, 4 months, 6 months
Cold Intensity Score
Comparison of Cold Intensity Score (CIS) values
Time frame: Baseline, 2 months, 4 months, 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in Apr 2023, 6 months.
Of 27 industry-sponsored interventional studies with no phase under Respiratory Tract Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 6 months is close to that.
Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Tract Infections →
AronPharma Sp. z o. o.